Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marguerite RoAD: Gantenerumab in mild Alzheimer's disease
NCT02051608Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2014
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Started Mar 2014; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02051608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051608.